|
Mechanismβ2-adrenergic receptor agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date13 Jan 1973 |
100 Clinical Results associated with GlaxoSmithKline Intellectual Property Ltd.
0 Patents (Medical) associated with GlaxoSmithKline Intellectual Property Ltd.
100 Deals associated with GlaxoSmithKline Intellectual Property Ltd.
100 Translational Medicine associated with GlaxoSmithKline Intellectual Property Ltd.